New heart valve device offers hope for High-Risk patients in china

NCT ID NCT04982588

First seen Dec 08, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This study tests a new heart valve device (CoreValve Evolut PRO) in 52 Chinese patients with severe aortic stenosis who are too high-risk for open-heart surgery. The valve is inserted through a tube in the artery, avoiding major surgery. Researchers are checking how many patients survive and whether the new valve works well without leaking.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE, SYMPTOMATIC AORTIC STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100000, China

  • Chinese PLA General Hospital, Chinese PLA Medical School

    Beijing, Beijing Municipality, 100000, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310009, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610000, China

Conditions

Explore the condition pages connected to this study.